The EACR Conference on Liquid Biopsies will provide a comprehensive overview of liquid biopsies in cancer. It will cover what is already in clinical practice, what is on the horizon in cancer patient management and the latest techniques and applications for detecting solid tumours using liquid biopsies.

Liquid biopsies are demonstrating the potential to support early detection and screening of cancer; as a prognostic tool, to predict treatment efficacy or resistance, to evaluate treatment toxicity and to monitor minimal residual disease and anticipate disease relapse. The diversity and combination of cancer analytes in blood (including cell-free DNA, cfRNA, CTCs, extracellular vesicles and proteins) have the potential to boost liquid biopsy utility further.

This conference, with its slate of recognised experts in many aspects of liquid biopsy research will explore how complex multi-modal liquid biopsy (circulating nucleic acids,  circulating tumour cells, circulating proteins and extracellular vesicles) assays could be taken from the laboratory into clinical practice.

Target audience

• Translational scientists
• Biologists
• Geneticists
• Data scientists
• Molecular pathologists
• Bioengineers
• Oncologists
• Patient advocates
• Primary care (GPs)
• Radiologists
• Clinical and non-clinical trainees
• Biotech and diagnostic companies
• Pharmaceutical companies

Topics to be covered:

• Implementation of liquid biopsy in clinical trials
• Applications for CTCs
• Basic biology for biomarker discovery
• New techniques enhancing liquid biopsy
• Integration of multiple blood-based analytes for multi-modal biomarkers
• Artificial Intelligence applied to liquid biopsy